Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study
Open Access
- 9 May 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (10) , 2787
Abstract
Background/Objectives: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disease. Neuropathic pain (NP), related to peripheral inflammation, is among its earliest manifestations. This preliminary open-label investigation aimed to evaluate the efficacy of ultramicronized Palmitoylethanolamide (umPEA) in the management of NP. Methods: A total of 14 patients with CIDP, already undergoing immunoglobulin (Ig) therapy, were divided into two groups: Group A received umPEA 600 mg twice daily in addition to Ig for 60 days, followed by Ig alone until the end of the observation (180 days); Group B received Ig alone for 120 days and subsequently umPEA + Ig in the last 60 days of the study. Painful symptom intensity and quality of life were assessed by the Numeric Rating Scale, Neuropathic Pain Symptoms Inventory, and Five Dimensions Health Questionnaire. The safety umPEA profile was evaluated. Results: UmPEA in addition to immunoglobulins allowed for a significant improvement over time in all NP symptoms intensity (p = 0.0007) and in patients’ quality of life (p = 0.0036). Conclusions: This study suggests umPEA as a safe and effective treatment in addition to immunoglobulins to improve NP, ameliorating the patient’s health status. These results highlight the importance of neuroinflammation modulation in the management of CIDP’s painful symptoms, drawing attention to umPEA’s potential use also in neuropathies of different etiologies.Keywords
This publication has 61 references indexed in Scilit:
- Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathyMuscle & Nerve, 2021
- Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathyQuality of Life Research, 2021
- Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patientsAnnals of Clinical and Translational Neurology, 2021
- Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)Journal of Neurology, 2020
- Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathyJournal of Neurology, 2017
- Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsCochrane Database of Systematic Reviews, 2017
- Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic painInflammopharmacology, 2013
- Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseasesNeurological Sciences, 2009
- Pain affects the quality of life of neuropathic patientsNeurological Sciences, 2006
- Pain assessmentEuropean Spine Journal, 2005